Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Policy / Regulatory

China Drug Procurement: Centralized Rules Shape 11th Round Of VBP

Fineline Cube Sep 23, 2025

The Joint Procurement Office of the National Healthcare Security Administration (NHSA) published the definitive rules...

Company Deals Drug

Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS

Fineline Cube Sep 23, 2025

China‑based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd....

Company Drug

Roche’s SC Lunsumio Gains CHMP Recommendation for Relapsed Follicular Lymphoma

Fineline Cube Sep 23, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products...

Company Drug

Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study

Fineline Cube Sep 23, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Phase III evERA trial has met both co‑primary...

Medical Device

Shanghai Sanyou Medical’s Agloe Robot Enters Chinese NMPA Special Review for Innovative Spine Devices

Fineline Cube Sep 23, 2025

Shanghai Sanyou Medical Co., Ltd. (SHA: 688085) announced that its affiliate Agloe Medical Technologies has...

Company Drug

Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR

Fineline Cube Sep 23, 2025

Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau‑protein antibody etalanetug (E2814) has...

Company Deals Drug

Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline

Fineline Cube Sep 23, 2025

Pfizer Inc. (NYSE: PFE) announced today that it will acquire Metsera, Inc. (NASDAQ: MTSR), a...

Company Drug

Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B

Fineline Cube Sep 23, 2025

Youcare Pharmaceutical Group (SHA: 688658) announced that the U.S. Food and Drug Administration (FDA) has...

Policy / Regulatory

National Healthcare Security Administration Announces Nationwide Pilot for Real‑World Medical‑Insurance Value Evaluation

Fineline Cube Sep 23, 2025

The National Healthcare Security Administration (NHSA) today issued a notice outlining a multi‑city pilot program...

Company Drug

Huadong Medicine Secures FDA IND Approval for HDM2017 ADC

Fineline Cube Sep 23, 2025

Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration...

Company Drug

Sichuan Kelun‑Biotech’s A400 Receives NDA Acceptance in China

Fineline Cube Sep 23, 2025

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the Center for Drug Evaluation...

Company Drug

Visen Pharmaceuticals Secures Hainan Approval for Palopegteriparatide

Fineline Cube Sep 23, 2025

Visen Pharmaceuticals (HKG: 2561) announced today that its innovative drug palopegteriparatide (TransCon PTH) has received official...

Company Drug

Stone Pharmaceuticals Launches CS2009 Phase II Trial in Australia

Fineline Cube Sep 23, 2025

CStone Pharmaceuticals (HKG: 2616) announced today that the first patient has been dosed in Australia...

Company Drug

Nanjing Leads Biolabs Secures FDA IND for LBL‑047, a First‑In‑Class Bispecific Fusion Protein

Fineline Cube Sep 23, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug...

Company Deals

China’s Insilico, Mabwell, and Chemexpress Forge AI‑Driven ADC Collaboration

Fineline Cube Sep 22, 2025

Insilico Medicine, a global leader in generative AI‑driven drug discovery, announced a strategic partnership with...

Policy / Regulatory

NHSA Completes 2025 Drug Negotiation Review; CAR‑T Therapies Clear the Hurdle

Fineline Cube Sep 22, 2025

The National Healthcare Security Administration (NHSA) announced today that the expert review for the 2025...

Company Drug

Shenzhen Salubris Submits NMPA NDA for SAL003, a Once‑Monthly Anti‑PCSK9 Biologic

Fineline Cube Sep 22, 2025

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that it has filed a New Drug...

Company Deals

Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex DRx Implant Development

Fineline Cube Sep 22, 2025

Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts‑based Alcyone Therapeutics. The deal centers on...

Company Drug

Henlius Organon Secure EU Marketing Approval for BILDYOS and BILPREVDA Denosumab Biosimilars

Fineline Cube Sep 22, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Commission...

Company Drug

Innovent Secures 2nd NMPA Approval for Mazdutide – First Dual GLP‑1/GCGR Therapy for Type 2 Diabetes

Fineline Cube Sep 22, 2025

Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second...

Posts pagination

1 … 77 78 79 … 643

Recent updates

  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
  • China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio
  • Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.